Joseph Pantginis has joined Rodman & Renshaw in equity research as a managing director covering biotechnology.
Dr. Pantginis has over 15 years of sell-side experience covering biotechnology companies, having spent most of those years at Roth Capital Partners and Canaccord Adams.
Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he founded the retrovirus core facility, providing molecular biology service and retroviral vectors to a broad range of Regeneron’s research programs. His therapeutic focus is oncology, as well as regenerative medicine and gene therapy.
In a statement, Edward Silvera, COO of Rodman, said Mr. Pantginis’ extensive experience in the sector and his reputation for providing highly analytical advice to investors will further enhance Rodman’s ability to provide clients with superior service.
